Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps
1. BAX reported Q1 2025 adjusted EPS at 62 cents, exceeding expectations. 2. Sales reached $2.63 billion, growing 5% year-over-year, beating consensus. 3. Medical Products & Therapies segment sales grew 3%, driven by strong IV demand. 4. Guidance for 2025 EPS raised to $2.47-$2.55, indicating optimistic growth. 5. Stock rose 4.38% to $32.54 following the positive report.